Merseyside Inter Agency Drug Misuse Database

January - March 2011

Halton DAAT

Quarter 4 2010/11

Martin Chandler and Steven Griffith

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:

Martin Chandler

IAD Manager

Centre for Public Health

Faculty of Health & Applied Social Sciences

Liverpool John Moores University

2nd Floor, Henry Cotton Campus,

15-21 Webster Street, Liverpool.

L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith

IAD Researcher

(0151) 231 4309

S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

Contents

National Drug Treatment Monitoring System (NDTMS) **20**

Combined Datasets **24**

Cross Matched Datasets **25**

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2010/11)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request.

Table 1: Arrest referral Current Quarter; Individuals assessed, by Gender & Age Group

Gender	n	%
Male	5	100.0
Female	0	0.0
Age Group		
Under 18	0	0.0
18-19	0	0.0
20-24	0	0.0
25-29	2	40.0
30-34	2	40.0
35-39	0	0.0
40-44	1	20.0
45+	0	0.0
Total	5	100

Table 2: Arrest Referral Year to Date ; by Gender & Age Group

	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	2.9	0	0.0	1	2.6
20-24	9	26.5	0	0.0	9	23.7
25-29	11	32.4	1	25.0	12	31.6
30-34	6	17.6	2	50.0	8	21.1
35-39	2	5.9	0	0.0	2	5.3
40-44	4	11.8	0	0.0	4	10.5
45+	1	2.9	1	25.0	2	5.3
Total	34	100	4	100	38	100

Table 3: Arrest Referral Current Quarter; Individuals assessed, by Gender & Age Group - Halton Residents Only* (Includes clients seen in other DA(A)T areas)

Gender	n	%
Male	10	90.9
Female	1	9.1
Age Group		
Under 18	0	0.0
18-19	0	0.0
20-24	1	9.1
25-29	5	45.5
30-34	4	36.4
35-39	0	0.0
40-44	1	9.1
45+	0	0.0
Total	11	100

*Table 3 figures are based on DAT of Residence, NOT DAT of contact as with all other Arrest Referral data.

Table 4: Arrest Referral Current Quarter; Reported Main Drug(s)* of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	0	0	0
Benzodiazepines	0	0	0
Cannabis	0	0	0
Crack	0	0	0
Cocaine	0	1	0
Ecstasy	0	0	0
Heroin	2	1	0
Methadone	0	0	0
Other	0	0	0

1 individual did not report a main drug of use

Table 5: Arrest Referral Year to Date ; Reported Main Drug(s)* of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	2	1	0
Benzodiazepines	0	0	0
Cannabis	7	0	0
Crack	2	1	0
Cocaine	1	4	0
Ecstasy	0	0	0
Heroin	11	5	1
Methadone	1	0	0
Other	0	0	0

2 individuals did not report a main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

PROBATION

Quarter 4 (2010/11)

NB: Due to ongoing issues we are unable to provide Probation data for this report. This situation is being resolved and we anticipate being able to include this section in future reports. ASRO reporting is provided as usual.

Current Quarter; ASROs

- 6 ASROs were commenced during Q4
- 5 Individuals commenced ASROs during Q4
- 5 ASROs were terminated during Q4
- 4 Individuals had their ASROs terminated during Q4

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2010/11)

Introduction

Data are collected directly from needle and syringe programmes (NSPs) including Addaction outreach. Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY NSP

Table 6: Agency NSP Current Quarter; Individuals by Gender

New Clients	n	%
Male	82	93.2
Female	6	6.8
Total	88	100
All Clients		
Male	242	95.7
Female	11	4.3
Total	253	100

Table 7: Agency NSP Current Quarter; Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	8	72.7
Female	3	27.3
Total	11	100
All Clients		
Male	67	89.3
Female	8	10.7
Total	75	100

Table 8: Agency NSP Current Quarter; Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	8	9.1	11	4.3
20-24	20	22.7	54	21.3
25-29	30	34.1	66	26.1
30-34	8	9.1	40	15.8
35-39	11	12.5	32	12.6
40-44	7	8.0	30	11.9
45+	4	4.5	20	7.9
Total	88	100	253	100

Table 9: Agency NSP Current Quarter; Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	2	2.7
20-24	3	27.3	9	12.0
25-29	2	18.2	9	12.0
30-34	2	18.2	15	20.0
35-39	2	18.2	14	18.7
40-44	1	9.1	14	18.7
45+	1	9.1	12	16.0
Total	11	100	75	100

Table 10: Agency NSP Current Quarter; Gender by Age Group of Individuals

Age Group	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	9	3.7	2	18.2
20-24	51	21.1	3	27.3
25-29	65	26.9	1	9.1
30-34	39	16.1	1	9.1
35-39	31	12.8	1	9.1
40-44	28	11.6	2	18.2
45+	19	7.9	1	9.1
Total	242	100	11	100

Table 11: Agency NSP Current Quarter; Gender by Age Group: Steroid Users Omitted

Age Group	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	3.0	0	0.0
20-24	6	9.0	3	37.5
25-29	8	11.9	1	12.5
30-34	14	20.9	1	12.5
35-39	14	20.9	0	0.0
40-44	12	17.9	2	25.0
45+	11	16.4	1	12.5
Total	67	100	8	100

Table 12: Agency NSP Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	16	3.8	3	13.6	19	4.2
20-24	93	21.8	3	13.6	96	21.4
25-29	124	29.1	3	13.6	127	8.3
30-34	71	16.7	2	9.1	73	16.3
35-39	50	11.7	3	13.6	53	11.8
40-44	42	9.9	6	27.3	48	10.7
45+	30	7.0	2	9.1	32	7.1
Total	426	100	22	100	448	100

Table 13: Agency NSP Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	2	2.0	1	6.7	3	2.6
20-24	11	11.1	3	20.0	14	12.3
25-29	14	14.1	2	13.3	16	14.0
30-34	19	19.2	1	6.7	20	17.5
35-39	19	19.2	4	26.7	21	18.4
40-44	19	19.2	4	26.7	23	20.2
45+	15	15.2	2	13.3	17	14.9
Total	99	100	15	100	114	100

Table 14: Current Quarter; Main Drug of Use for New Agency NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	4	4.9	2	33.3
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	2	2.4	0	0.0
Methadone	0	0.0	0	0.0
Steroids	74	90.2	3	50.0
Morphine	0	0.0	0	0.0
Unknown	2	2.4	1	16.7
Total	82	100	6	100

Table 15: Current Quarter; Main Drug of Use for All NSP Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	2	0.8	0	0.0
Heroin	17	7.0	1	9.1
Methadone	14	5.8	1	9.1
Morphine	2	0.8	1	9.1
Steroids	175	72.3	3	27.3
Various	0	0.0	0	0.0
Other	0	0.0	0	0.0
Unknown	32	13.2	5	45.5
Total	242	100	11	100

Table 16: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

Drug of Use	Gender			
	Male		Female	
	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	1	4.8
Crack	2	0.5	0	0.0
Heroin	29	6.8	2	9.5
Methadone	21	4.9	2	9.5
Morphine	3	0.7	1	4.8
Steroids	327	76.8	6	28.6
Various	8	1.9	3	14.3
Other	0	0.0	0	0.0
Unknown	36	8.4	6	28.6
Total	426	100	21	100

Table 17: Main Drug of Use for All Agency Syringe Exchange Clients, by Age Group

Age Group	Amphetamine		Cocaine/ Crack		Heroin/ Morphine		Methadone		Steroids		Unknown	
	n	%	n	%	n	%	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0	0	0.0	9	5.1	2	5.4
20-24	0	0.0	0	0.0	0	0.0	1	6.7	45	25.3	8	21.6
25-29	0	0.0	2	100	1	4.8	2	13.3	57	32.0	4	10.8
30-34	0	0.0	0	0.0	5	23.8	4	26.7	25	14.0	6	16.2
35-39	0	0.0	0	0.0	3	14.3	3	20.0	18	10.1	8	21.6
40-44	0	0.0	0	0.0	8	38.1	2	13.3	16	9.0	4	10.8
45+	0	0.0	0	0.0	4	19.0	3	20.0	8	4.5	5	13.5
Total	0	0.0	2	100	21	100	15	100	178	100	37	100

* % Totals are by drug, not Age Group

PHARMACY NSPs

Table 18: Pharmacy NSP Current Quarter; Individuals by Gender

New Clients	n	%
Male	21	91.3
Female	2	8.7
Total	23	100
All Clients		
Male	62	96.9
Female	2	3.1
Total	64	100

Table 19: Pharmacy NSP Current Quarter; Individuals by Site

	Individuals	
PNSP Site	**n**	**%**
Superdrug Runcorn	0	0.0
Castlefield Health Centre Runcorn	30	46.9
Murdishaw Pharmacy Runcorn	3	4.7
Co-op Albert Road Widnes	0	0.0
Lloyds Albert Road Widnes	31	48.4
Co-op Peelhouse Lane Widnes	0	0.0
Total	64	100

Table 20: Pharmacy NSP Current Quarter; Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	2	8.7	3	4.7
20-24	2	8.7	4	6.3
25-29	2	8.7	4	6.3
30-34	6	26.1	18	28.1
35-39	4	17.4	13	20.3
40-44	4	17.4	14	21.9
45+	3	13.0	8	12.5
Total	23	100	64	100

Table 21: Current Quarter; Main Drug of Use for All Pharmacy NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	3	4.8	0	0.0
Methadone	0	0.0	0	0.0
Morphine	1	1.6	0	0.0
Steroids	3	4.8	0	0.0
Unknown	55	88.7	2	100.0
Total	62	100	2	100

Table 22: Year to Date; Main Drug of Use for All Pharmacy NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	6	4.5	4	30.8
Methadone	0	0.0	1	7.7
Morphine	1	< 1	0	0.0
Steroids	5	3.7	0	0.0
Unknown	122	91.0	8	61.5
Total	134	100	13	100

Table 23: Pharmacy NSP Year to Date; by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	3	2.2	0	0.0	3	2.0
20-24	10	7.5	3	23.1	13	8.8
25-29	13	9.7	1	7.7	14	9.5
30-34	37	27.6	6	46.2	43	29.3
35-39	23	17.2	1	7.7	24	16.3
40-44	27	20.1	2	15.4	29	19.7
45+	21	15.7	0	0.0	21	14.3
Total	134	100	13	100	147	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 24: Current Quarter; Individuals in Agency and Pharmacy NSP, by Gender

New Clients	n	%
Male	103	92.8
Female	8	7.2
Total	111	100
All Clients		
Male	293	95.8
Female	13	4.2
Total	306	100

Table 25: Current Quarter; Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	29	85.3
Female	5	14.7
Total	34	100
All Clients		
Male	115	125
Female	10	8.0
Total	125	100

*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

Table 26: Current Quarter; Individuals in Agency and Pharmacy NSP , by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	10	9.0	14	4.6
20-24	22	19.8	58	19.0
25-29	32	28.8	70	22.9
30-34	14	12.6	53	17.3
35-39	15	13.5	43	14.1
40-44	11	9.9	42	13.7
45+	7	6.3	26	8.5
Total	111	100	306	100

Table 27: Current Quarter; Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	5.9	5	4.0
20-24	5	14.7	12	9.6
25-29	4	11.8	13	10.4
30-34	8	23.5	27	21.6
35-39	6	17.6	24	19.2
40-44	5	14.7	26	20.8
45+	4	11.8	18	14.4
Total	34	100	125	100

Table 28: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	20	2.9	5	10.9	25	3.4
20-24	121	17.3	11	23.9	132	17.7
25-29	194	27.8	5	10.9	199	26.7
30-34	134	19.2	8	17.4	142	19.1
35-39	99	14.2	4	8.7	103	13.8
40-44	72	10.3	10	21.7	82	8.2
45+	58	8.3	3	6.5	61	8.2
Total	698	100	46	100	744	100

Table 29: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	17,239	1,951	19,190	60,481

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

NSP SERVICE ACTIVITY SUMMARY

Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

Table 30: Current Quarter; All NSP transactions by NSP Type

All Transactions	n	%
Halton DDC	342	64.9
Pharmacy NSPs	185	35.1
Total	527	100

Fig 1: Current Quarter NSP Service Activity; Transactions by NSP Type

Table 31: Current Quarter; NSP Transactions, Attributable Data

All Attributable Transactions	n	%*
Halton DDC	342	65.1
Pharmacy NSPs	183	34.9
Total	525	100

*Represents proportion of transactions that were attributable during the current quarter.

Table 32: Current Quarter; PNSP Transactions and Individuals by Site

PNSP Site	Transactions		Individuals	
	n	%	n	%
Superdrug Runcorn	0	0.0	0	0.0
Castlefield Health Centre Runcorn	86	46.5	30	46.9
Murdishaw Pharmacy Runcorn	30	16.2	3	4.7
Co-op Albert Road Widnes	0	0.0	0	0.0
Lloyds Albert Road Widnes	69	37.3	31	48.4
Co-op Peelhouse Lane Widnes	0	0.0	0	0.0
Total	185	100	64	100

Table 33: Current Quarter; All NSP Individuals by NSP Type

All Clients	n	%
Halton DDC	253	79.8
Pharmacy NSPs	64	20.2
Total	317	100

Fig 2: Current Quarter NSP Service Activity; Individuals by NSP Type

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2010/11)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

Table 34: NDTMS Current Quarter; Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	39	79.6
Female	10	20.4
Total	49	100
All Clients		
Male	500	73.6
Female	179	26.4
Total	679	100

Table 35: Year to Date, by Gender

New Clients		
Male	154	73.0
Female	57	27.0
Total	211	100
All Clients		
Male	528	73.6
Female	189	26.4
Total	717	100

Table 36: NDTMS Current Quarter; Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	6	12.2	61	9.0
18-19	1	2.0	19	2.8
20-24	5	10.2	84	12.4
25-29	9	18.4	133	19.6
30-34	9	18.4	142	20.9
35-39	6	12.2	125	18.4
40-44	8	16.3	66	9.7
45+	5	10.2	49	7.2
Total	49	100	679	100

Table 37: NDTMS Year to Date; Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	29	13.7	65	9.1
18-19	11	5.2	21	2.9
20-24	33	15.6	88	12.3
25-29	32	15.2	136	19.0
30-34	34	16.1	148	20.6
35-39	41	19.4	134	18.7
40-44	20	9.5	71	9.9
45+	11	5.2	54	7.5
Total	211	100	717	100

Table 38: NDTMS Current Quarter; Individuals Reporting Alcohol as Primary substance and Amphetamine/Opiate/Crack as Secondary Substance

New Clients	n	%
Male	0	-
Female	0	-
Total	0	-

Table 39: NDTMS Current Quarter; Ethnicity of Individuals in Contact with Treatment Services

	New Clients		All Clients	
Ethnicity	**n**	**%**	**n**	**%**
White British	49	100.0	670	98.7
White Irish	0	0.0	2	< 1
Other White	0	0.0	1	< 1
White & Black Caribbean	0	0.0	1	< 1
White & Asian	0	0.0	0	0.0
Other Asian	0	0.0	1	< 1
Other Mixed	0	0.0	1	< 1
Caribbean	0	0.0	3	< 1
Chinese	0	0.0	0	0.0
Other	0	0.0	0	0.0
Unknown	0	0.0	0	0.0
Total	49	100	679	100

Table 40: NDTMS Current Quarter; Individuals in Contact with Treatment Services, by Main Drug of Use

	New Clients		All Clients	
Drug of Use	**n**	**%**	**n**	**%**
Heroin	17	34.7	398	58.6
Methadone	3	6.1	45	6.6
Other Opiates	3	6.1	18	2.7
Benzodiazepines	0	0.0	3	< 1
Amphetamines	0	0.0	17	2.5
Cocaine	11	22.4	59	8.7
Crack	0	0.0	9	1.3
Hallucinogens	0	0.0	0	0.0
Ecstasy	0	0.0	0	0.0
Cannabis	10	20.4	116	17.1
Antidepressants	0	0.0	1	< 1
Prescription Drugs	3	6.1	8	1.2
Mephedrone	1	2.0	2	< 1
Other/Unknown	1	2.0	3	< 1
Total	49	100	679	100

COMBINED DATASETS

Quarter 4 (2010/11)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSPs (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 41: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	741	79.7
Female	189	20.3
Age Group		
Under 18	61	6.6
18-19	33	3.5
20-24	140	15.1
25-29	189	20.3
30-34	181	19.5
35-39	163	17.5
40-44	97	10.4
45+	66	7.1
Total	930	100

Table 42: Year to Date, by Gender and Age Group

	Gender				*Total in Age Group*	
	Male		**Female**			
Age Group	n	%	n	%	*n*	*%*
Under 18	53	4.6	12	5.3	65	4.7
18-19	38	3.3	7	3.1	45	3.3
20-24	182	15.8	36	15.8	218	15.8
25-29	271	23.5	42	18.4	313	22.6
30-34	218	18.9	55	24.1	273	19.7
35-39	183	15.8	35	15.4	218	15.8
40-44	118	10.2	25	11.0	143	10.3
45+	92	8.0	16	7.0	108	7.8
Total	1,155	100	228	100	1,383	100

# CROSS-MATCHED DATASETS
Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.

Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets

AGENCY (75) Male 34 Female 3 NDTMS (679)

Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets

PHARMACY (64) Male 24 Female 1 NDTMS (679)

Fig 5: Year to Date Crossover between Agency NSP and NDTMS datasets

| AGENCY (114) | Male 50 Female 5 | NDTMS (717) |

Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

| PHARMACY (147) | Male 42 Female 4 | NDTMS (717) |